Clinical Trial Update: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether continuing versus interrupting imatinib after 3 years of adjuvant therapy improves outcomes in patients with resected, high-ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED